• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase I study of camrelizumab in patients with advanced solid tumors.

作者信息

Ma Yuxiang, Cao Jiaxin, Zhang Yang, Liu Qianwen, Fang Wenfeng, Yang Yunpeng, Zhao Yuanyuan, Yang Qing, Zhao Hongyun, Zhang Li

机构信息

Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, People's Republic of China.

Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, People's Republic of China.

出版信息

Signal Transduct Target Ther. 2023 Feb 1;8(1):47. doi: 10.1038/s41392-022-01213-6.

DOI:10.1038/s41392-022-01213-6
PMID:36725836
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9892498/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4823/9892498/3a73b3f1946b/41392_2022_1213_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4823/9892498/3a73b3f1946b/41392_2022_1213_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4823/9892498/3a73b3f1946b/41392_2022_1213_Fig1_HTML.jpg

相似文献

1
Phase I study of camrelizumab in patients with advanced solid tumors.卡瑞利珠单抗治疗晚期实体瘤患者的I期研究。
Signal Transduct Target Ther. 2023 Feb 1;8(1):47. doi: 10.1038/s41392-022-01213-6.
2
Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.卡瑞利珠单抗，一种针对程序性死亡受体 1 的人源化单克隆抗体的现状与展望。
Recent Pat Anticancer Drug Discov. 2021;16(3):312-332. doi: 10.2174/1574892816666210208231744.
3
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.卡瑞利珠单抗在澳大利亚晚期或转移性癌症患者中的首次人体剂量探索研究。
Drug Des Devel Ther. 2020 Mar 18;14:1177-1189. doi: 10.2147/DDDT.S243787. eCollection 2020.
4
Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.SHR7390 单药或联合卡瑞丽珠单抗治疗晚期实体瘤的安全性和临床活性：两项 I 期试验结果。
Oncologist. 2023 Jan 18;28(1):e36-e44. doi: 10.1093/oncolo/oyac225.
5
Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial.卡瑞利珠单抗治疗错配修复缺陷或微卫星高度不稳定的晚期或转移性实体瘤患者的开放性前瞻性关键试验。
J Cancer Res Clin Oncol. 2020 Oct;146(10):2651-2657. doi: 10.1007/s00432-020-03251-5. Epub 2020 Jul 4.
6
The clinical application of camrelizumab on advanced hepatocellular carcinoma.卡瑞利珠单抗治疗晚期肝细胞癌的临床应用。
Expert Rev Gastroenterol Hepatol. 2020 Nov;14(11):1017-1024. doi: 10.1080/17474124.2020.1807939. Epub 2020 Aug 18.
7
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.卡瑞利珠单抗联合化疗对比安慰剂用于治疗晚期或转移性食管鳞癌患者的生存和无进展生存期的影响：ESCORT-1 期随机临床试验。
JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836.
8
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.卡瑞利珠单抗对比研究者选择的化疗作为晚期或转移性食管鳞癌（ESCORT）二线治疗：一项多中心、随机、开放标签、III 期研究。
Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13.
9
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
10
Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.多瘤种患者抗 PD-1 抗体卡瑞利珠单抗的群体药代动力学及模型指导的剂量策略。
Acta Pharmacol Sin. 2021 Aug;42(8):1368-1375. doi: 10.1038/s41401-020-00550-y. Epub 2020 Nov 5.

引用本文的文献

1
Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma.回顾性评估新辅助卡瑞利珠单抗联合诱导化疗：在晚期下咽及喉鳞状细胞癌保喉中的疗效。
Cancer Immunol Immunother. 2024 Feb 15;73(3):54. doi: 10.1007/s00262-023-03579-0.
2
Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study.评估卡瑞利珠单抗联合阿帕替尼对比索拉非尼治疗原发性肝癌的有效性：一项单中心回顾性研究。
Sci Rep. 2023 Aug 16;13(1):13285. doi: 10.1038/s41598-023-40030-x.

本文引用的文献

1
CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.抗 CCR5 抗体 Leronlimab 治疗后外周血 CCR5+CD4+T 细胞增加的 CCR5 受体占有率分析。
Front Immunol. 2021 Nov 19;12:794638. doi: 10.3389/fimmu.2021.794638. eCollection 2021.
2
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.卡瑞利珠单抗联合化疗对比安慰剂用于治疗晚期或转移性食管鳞癌患者的生存和无进展生存期的影响：ESCORT-1 期随机临床试验。
JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836.
3
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.
卡瑞利珠单抗在澳大利亚晚期或转移性癌症患者中的首次人体剂量探索研究。
Drug Des Devel Ther. 2020 Mar 18;14:1177-1189. doi: 10.2147/DDDT.S243787. eCollection 2020.
4
Receptor occupancy measurement of anti-PD-1 antibody drugs in support of clinical trials.抗PD-1抗体药物的受体占有率测量以支持临床试验。
Bioanalysis. 2019 Jul;11(14):1347-1358. doi: 10.4155/bio-2019-0090. Epub 2019 Aug 8.
5
Camrelizumab: First Global Approval.卡瑞利珠单抗：全球首次获批。
Drugs. 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0.